05/08/2019 – AB Science provides an update on its masitinib clinical program. Post navigationPreviousPrevious post:Results of masitinib study in metastatic melanomaNextNext post:AB Science to present at two upcoming conferences in September 2019Related PostsPublication of new results in in the peer-reviewed journal Glia that further support masitinib’s potential mode of action in ALSDecember 23, 2019Publication of three AB8939 scientific abstracts in the special ASH Annual Meeting issue of BloodDecember 9, 2019Webcast on masitinib in severe asthma on Monday, December 2, 2019November 26, 2019Summary of webcast with Key Opinion Leaders on Indolent Systemic MastocytosisNovember 25, 2019Clarification regarding the article in the newspaper Les Echos related to the investigation by the French market authoritiesNovember 22, 2019Positive top-line Phase 3 results for masitinib in severe asthmaNovember 7, 2019
Publication of new results in in the peer-reviewed journal Glia that further support masitinib’s potential mode of action in ALSDecember 23, 2019
Publication of three AB8939 scientific abstracts in the special ASH Annual Meeting issue of BloodDecember 9, 2019
Clarification regarding the article in the newspaper Les Echos related to the investigation by the French market authoritiesNovember 22, 2019